Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Hall, W. D.
space
  arrow  Israili, Z. H.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

REPLY

Does Race Predispose to Angiotensin-associated Angioneurotic Edema?

right arrow W. Dallas Hall and Zafar H. Israili

15 December 1993 | Volume 119 Issue 12 | Page 1224


IN RESPONSE:

The observation of Drs. Brown and Nadeau is interesting. As they note, the data are insufficient to confirm the observed disparity in the incidence of ACE inhibitor-induced angioneurotic edema between blacks and whites. Angioneurotic edema was not one of the adverse effects reported in a study of 112 black patients with hypertension who were treated with captopril [1]. We agree with Drs. Brown and Nadeau that rigorous pharmacoepidemiologic studies are needed to confirm or refute their observation. It appears that women are at a greater risk for the development of angioneurotic edema from ACE inhibitors [2]. We suggest that all subsequent reports of angioneurotic edema associated with ACE inhibitors should include the race of the patients.


References
space
up arrowTop
dotReferences

1. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A comparison of the efficacy and safety of a ß-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990; 150:1707-13.

2. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992; 117:234-42.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Hall, W. D.
space
  arrow  Israili, Z. H.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online